Tellgen Corp
300642
Company Profile
Business description
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Contact
No. 412 Huiqing Road
Pudong New District
Shanghai201201
CHNT: +86 2150495115
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
522
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.60 | 29.50 | 0.33% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,727.80 | 27.10 | 0.31% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |